The Relative Strength (RS) Rating for Illumina entered a new percentile Wednesday, as it got a lift from 66 to 74.
This exclusive rating from Investor's Business Daily identifies price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history shows that the market's biggest winners tend to have an 80 or better RS Rating as they begin their largest climbs. See if Illumina can continue to show renewed price strength and hit that benchmark.
How To Invest In Stocks In Both Bull And Bear Markets
While it's not currently an ideal time to buy shares, see if the stock goes on to offer and clear an appropriate buy point.
Top and bottom line growth moved higher in the company's most recent quarter. Earnings were up 245%, compared to 13% in the prior report. Revenue increased from -5% to -3%.
Illumina earns the No. 9 rank among its peers in the Medical-Research Equipment/Services industry group. Veracyte, Natera and Centessa Pharma ADR are among the top 5 highly rated stocks within the group.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
